The 2018 Equateur outbreak in western DR Congo was crushed by Ervebo ring vaccination, Inmazeb and Ebanga inside a clinical trial, and a US response footprint of roughly 90 deployed CDC subject-matter experts backed by US$266 million in USAID assistance for DRC Ebola programmes from 2018 onwards. The 2018 outbreak ended with 54 cases and 33 deaths in three months, controlled by Ervebo vaccination of 3,302 contacts. USAID's outbreak-response capacity was wound down in early 2025. Craig Spencer, the MSF Guinea 2014 veteran now at Brown University, told the same Friday panel that the agency's outbreak unit of "roughly 60 staff, including around 10 Ebola specialists, no longer exists in any operational form"1.
In 2018, those staff ran contact-tracing convoys out of Mbandaka, ferried Ervebo doses to Iboko and underwrote nine of every ten dollars spent on the DRC response. None of that workflow has a US institutional owner today. Africa CDC's 16 May coordination statement names US CDC as a response partner; the confirmation release from WHO AFRO lists WHO and partners but does not name deployed US CDC personnel2. The Idaho dairy H5N1 surge to 59 quarantined herds illustrates the simultaneous demand compression on the same federal response apparatus that would otherwise be the partner of record in Bunia and Mongbwalu. Ebola containment runs on logistics before it runs on bedside care; the embedded layer that supplied that logistics in 2018 is the layer that is now absent.
